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Article info ABSTRACT  
The results of comparative assessment of the diagnostic value of the 
respiratory urease test labeled with C14 for the diagnosis of 
Helicobacter pylori infection in patients peptic ulcer and chronic 
gastritis B compared with serological test and rapid urease test on 
biopsies from the gastric mucosa were presented in the article. The 
results of study revealed that the sensitivity of the method was almost 
the same (95%) compared to biopsy rapid urease test. It was shown that 
presents of available licensed equipment and simplicity creates 
opportunity to use this method in specialized centers and regional 
multidisciplinary medical institutions. 
 
The global issue of modern gastroenterology is to solve the problem of diagnosis, 
treatment and prevention of complications of Helicobacter-associated diseases of the 
digestive system [3]. Currently, there is unambiguous scientific evidence of the 
connection Helicobacter Pylori (HP) infection with chronic gastritis, gastric ulcer and 
duodenal ulcer, malignant tumors of the stomach-adenocarcinoma and extra nodal B-cell 
lymphoma, which puts the diagnosis of HP infection and the choice of optimal treatment 
regimens for this infection in a number of the most important tasks of modern medicine 
[1, 2]. The Maastricht Consensus V directly indicate: Statement 1: H. pylori are the most 
important risk factor for stomach cancer. Eradication is the most promising strategy for 
reducing the incidence of gastric cancer (Level of evidence: 1, Recommendations class: 
A) [9]. The great interest of practical doctors in HP infection stimulated the creation of 
many different methods of its diagnosis. These include both invasive methods for 
determining HP infection by histological, urease tests, and representing a large and 
promising interest is a non-invasive breath tests. In the same consensus as the "gold 
standard" for the control of eradication recommends respiratory urease test with C13 
labeled carbon. For all its informativeness, this technique has one limitation. This is the 
high cost of the equipment, which seriously limits its use in practical health care. An 
alternative to this technique is a carbon C14labeled breath test.C14 is a radioactive isotope 
that is a source of low-energy beta particles. Its use had a number of restrictions and was 
subject to strict control, so this option was less common. The main problem with the use 
of urease breath test (UBT C14- test) was the difficulty organization of work on the 
storage and transportation of radioactive drugs. In recent years, due to inroads into a new 
tech, equipment using small doses of carbon labeled C14 has been created and the above 
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sanitary standards have been cancelled. The application of microcapsules for packaging 
urea labeled with a radioactive isotope has minimized the difficulties associated with the 
storage, disposal and safety of this isotope. For example, in a number of countries, 
including China, India and European countries, the application of this technique does not 
require radioactive control [8]. In the US, the sale of microcapsules with urea labeled 
with carbon isotopes is allowed by the FDA on along with conventional medicines 
through the pharmacy network. In addition, the cost of equipment and consumable 
material at cost is quite acceptable for the budget of practical health care. Currently, this 
equipment and medicinal substance of carbon C14 are registered in the Pharmacological 
Committee of the Republic of Uzbekistan. 
Objective: Comparative evaluation of the sensitivity and specificity of the 
respiratory Urease test in patients with HP-associated diseases of the upper 
gastrointestinal tract (peptic ulcer and chronic gastritis B) compared with rapid urease 
and serological test for HP. 
Materials and methods. Studies were conducted in 40 patients (22 men and 18 
women, average age 45.5±3.6 years) with HP-associated diseases of the upper 
gastrointestinal tract (28 HP-associated chronic gastritis type B and 12 duodenal ulcer). 
Diagnosis verification was performed by esophagogastroduodenoscopy (EFGDS) with 
targeted biopsy and rapid urease test (ASAN Helicobacter Test, Republic of Korea) (Fig. 
1). 
 
Figure 1.The device for carrying a respiratory C14 urease test 
 
Also, these patients were assessed for HP infection by non-invasive respiratory 
urease test. A scintillation counter (HUBT-20PHelicobacterpyloridetector) was used to 
register the presence of C14 in the exhaled air. As a control, all patients also were 
determined of HP by serological method in blood serum. Patients were defined 
eradication therapy according to the recommendations of the Maastricht Consensus V, 
including Proton Pump Inhibitor, Amoxicillin, Clarithromycin and Bismuth Tricalium 
Dicitrate (De Nol) for 14 days. Control of the effectiveness of eradication therapy was 
carried out 4 weeks after the end of therapy. The control study included the determination 
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of HP by a rapid urease test and a respiratory Urease test. The digital material is 
processed by the method of variational statistics. 
The results of the study and their discussion: Studies conducted to assess the 
contamination of the gastric mucosa of patients with HP-associated chronic gastritis, 
showed that none of the using methods did not have 100% diagnostic information (Table. 
1). The sensitivity of the rapid urease test conducted on biopsy material was 97.5%. 
Similar results were obtained in a breath test with C14 carbon isotope. The sensitivity of 
the conducing technique during the serological study by enzyme immunoassay of blood 
serum was 95%. 
Table 1 
Indicators of gastric mucosa contamination in patients with chronic gastritis 
by various diagnostic methods 
Method of diagnosis of HP Before treatment, (HP+) After treatment (HP+) 
Number % Number % 
Rapid urease test 39 97,5 4 10% 
Respiratory C14test 39 97,5% 4 10% 
Serologicalmethod 38 95% 36 90% 
 
Conducted studies have revealed that the results of the rapid urease test and the 
respiratory C14 test were the same, where the effectiveness of eradication therapy was 
90%. Serological method of detection of antibodies to HP, as expected, did not have such 
information. 
As is well known, all existing methods of diagnosis of HP infection can be divided 
into direct and indirect. Direct methods can directly identify HP; indirect methods do not 
register the HP infection, but the consequences of its persistence in the body. As a 
method of primary diagnosis in persons who have indications for EFGDS, according to 
the Maastricht Protocols, it is recommended to use a rapid urease test from a biopsy 
selected by the antrum and the body of the stomach (Level of Evidence: 4 and 
Recommendations Class: C) [10]. 
HP in the process of its life activity produces the enzyme urease, which accumulates 
in the gastric mucosa. Urease decomposes urea to carbon dioxide and ammonium ions. 
To identify urease, the presence of which indicates the presence of HP, various 
biochemical techniques have been proposed. In diagnostic environments, necessarily 
including urea and indicator was placed biopsy material. If the environments begin to 
accumulate ammonium-the product of hydrolysis of urea urease, its pH changes and the 
indicator changes color. Urease test is simple to perform, does not require special 
qualification of medical personnel, relatively inexpensive, allows you to quickly get the 
response (depending on the modification of the test, the result can be obtained in a few 
minutes, at most after 24 hours) [6]. 
Despite the simplicity and availability of the biochemical method for detecting HP 
in biopsies of the gastric mucosa, it has a number of significant downsides. Urease tests 
give information of the presence of HP only in one area of the gastric mucosa; biopsies 
are not suitable for subsequent histological examination. These restrictions do not allow 
carrying out a clear correlation between its structural changes and urease activity in the 
same part of the gastric mucosa. 
The significant disadvantages include the possibility of obtaining false positive 
results, as it is shown that in patients with pathology of the gastrointestinal tract, its upper 
parts are populated by gram-negative bacteria, of which many species are able to produce 
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urease, and the most common in humans Proteus vulgaris and Proteus mirabilis are able 
to decomposed urea in the same time as HP [11]. In addition, the technique is invasive 
and the key positions of the Maastricht Consensus indicate: a suitable treatment strategy 
“Test and Strategy” the use of non-invasive methods of diagnosis and subsequent 
treatment in case of positive results [10]. 
Radionuclide methods of infection diagnostics (noninvasive and indirect) are based 
on urease activity of HP - urease respiratory tests with urea labeled with isotopes C13 and 
C14 [7]. In 1987, D. Graham et al. [5] published data on the first method labeled with C13 
urea, Campylobacter pylori in the gastric mucosa. Labeled urea is given to the patient as 
part of a trial breakfast. HP urease decomposes urea to carbon dioxide, preserving the 
labeled carbon. 
Carbon dioxide with blood flow is delivered to the lungs and excreted with exhaled 
air. The patient exhales into a special tube-container, and the air sample is sent for 
analysis. A scintillation counter is used to register the presence of C14 in the exhaled air. 
Since the respiratory test does not require esophagogastroscopy, this method is applicable 
in patients to whom it is contraindicated. This test gives information of all gastric mucosa 
and not a single fragment of it. Its sensitivity reaches 99% and specificity-98%. The high 
cost of the mass spectrometer limits the implementation of a breathing test using the 
isotope C13 [4]. 
As mentioned above, the emergence of new, innovative technologies have made it 
possible to conduct a test with the labeled isotope C14 without fear of its radioactive 
properties. The creation of new scintillation counters allowed the use of the drug C14 in 
extremely low dosages. As shown by our studies this technique has the same high (95%) 
sensitivity both in the primary diagnosis and in the control of eradication of HP infection. 
The availability of a licensed scintillation counter and C14 preparations, which differ from 
the traditional C13 breath test at an affordable cost, creates an almost real possibility of 
widespread use of this method of HP diagnosis at the level of practical health care. 
Summary: 
1. Respiratory urease test with C14 isotope has almost the same sensitivity (95%) 
compared to biopsy rapid urease test in the diagnosis of HP infection in patients with HP-
associated diseases of the digestive system. 
2. During control the eradication of HP infection from the gastric mucosa of 
patients with HP-associated gastrointestinal diseases, preference should be given to non-
invasive diagnosis using a respiratory C14 test. 
3. The availability of licensed equipment and consumables at affordable prices 
compared to the C13 test, the simplicity of the tests creates a real opportunity to use this 
technique in the conditions of both specialized centers and at the level of regional 
multidisciplinary medical institutions in accordance with clinical protocols for the 
diagnosis and treatment of diseases of the digestive system. 
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